ESSA Pharma (NASDAQ:EPIX) Shares Cross Above Fifty Day Moving Average of $5.52

Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $5.52 and traded as high as $6.44. ESSA Pharma shares last traded at $6.21, with a volume of 26,521 shares.

ESSA Pharma Trading Up 3.7 %

The firm has a 50-day moving average of $5.56 and a 200 day moving average of $6.20. The stock has a market capitalization of $285.70 million, a price-to-earnings ratio of -10.22 and a beta of 1.84.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.10. Equities research analysts predict that ESSA Pharma Inc. will post -0.71 EPS for the current fiscal year.

Institutional Trading of ESSA Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of EPIX. EntryPoint Capital LLC acquired a new stake in ESSA Pharma during the first quarter valued at approximately $38,000. BNP Paribas Financial Markets boosted its stake in shares of ESSA Pharma by 164.9% during the 4th quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after acquiring an additional 35,771 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of ESSA Pharma by 7.9% in the 1st quarter. Janus Henderson Group PLC now owns 1,175,242 shares of the company’s stock worth $9,978,000 after acquiring an additional 85,760 shares during the last quarter. Finally, RTW Investments LP acquired a new stake in shares of ESSA Pharma during the fourth quarter worth $15,171,000. Institutional investors own 75.12% of the company’s stock.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.